JOHN CHAPMAN: Open Payments
NPI 1184268617 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,501 in 153 payments from 17 companies in 2025. Trend: 2023 $3,602 · 2024 $3,798 · 2025 $3,501
Food & beverage: $3,501
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 66 | $1,685 |
| Gilead Sciences, Inc. | 31 | $593 |
| AstraZeneca Pharmaceuticals LP | 7 | $205 |
| EMD Serono, Inc. | 8 | $195 |
| Merck Sharp & Dohme LLC | 9 | $192 |
| Novo Nordisk Inc | 10 | $168 |
| Lilly USA, LLC | 4 | $82 |
| Napo Pharmaceuticals Inc | 4 | $75 |
| Antares Pharma, Inc. | 4 | $72 |
| Madrigal Pharmaceuticals | 2 | $52 |
Products named: CABENUVA, APRETUDE, RUKOBIA, PIFELTRO, DOVATO, FARXIGA, Wegovy, MOUNJARO.
Industry payments across TX — which companies pay providers there.
